Brokerages Set Catalent, Inc. (NYSE:CTLT) Price Target at $50.18

Shares of Catalent, Inc. (NYSE:CTLTGet Free Report) have received a consensus recommendation of “Hold” from the thirteen ratings firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $52.46.

A number of equities analysts have commented on CTLT shares. Royal Bank of Canada restated a “sector perform” rating and set a $63.50 price objective (up previously from $58.00) on shares of Catalent in a research report on Tuesday, February 6th. Barclays increased their price target on shares of Catalent from $45.00 to $47.00 and gave the company an “equal weight” rating in a report on Thursday, January 25th. Wells Fargo & Company cut their price target on shares of Catalent from $50.00 to $42.00 and set an “equal weight” rating for the company in a report on Thursday, November 16th. StockNews.com upgraded shares of Catalent to a “sell” rating in a report on Tuesday, February 6th. Finally, William Blair reiterated a “market perform” rating on shares of Catalent in a report on Tuesday, November 14th.

View Our Latest Stock Analysis on CTLT

Institutional Investors Weigh In On Catalent

Several hedge funds have recently modified their holdings of CTLT. Barclays PLC boosted its position in shares of Catalent by 578.0% in the second quarter. Barclays PLC now owns 3,385,660 shares of the company’s stock worth $146,802,000 after acquiring an additional 2,886,309 shares during the last quarter. Cadian Capital Management LP acquired a new stake in shares of Catalent in the second quarter worth approximately $120,456,000. Norges Bank acquired a new stake in shares of Catalent in the fourth quarter worth approximately $116,021,000. Capital World Investors boosted its position in shares of Catalent by 19.1% in the second quarter. Capital World Investors now owns 15,960,335 shares of the company’s stock worth $692,040,000 after acquiring an additional 2,556,699 shares during the last quarter. Finally, Castle Hook Partners LP acquired a new stake in shares of Catalent in the second quarter worth approximately $74,987,000.

Catalent Stock Up 0.5 %

Shares of Catalent stock opened at $56.99 on Tuesday. The company has a market cap of $10.29 billion, a P/E ratio of -8.38, a PEG ratio of 3.03 and a beta of 1.20. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.73 and a current ratio of 2.47. Catalent has a one year low of $31.45 and a one year high of $74.49. The firm has a fifty day moving average of $47.34 and a two-hundred day moving average of $44.83.

Catalent (NYSE:CTLTGet Free Report) last announced its quarterly earnings data on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.22). The firm had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.01 billion. Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The firm’s quarterly revenue was down 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.62 EPS. On average, analysts forecast that Catalent will post 0.52 earnings per share for the current year.

About Catalent

(Get Free Report

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.

Further Reading

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.